Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research interests include Prostate Cancer Treatment and Research, Cancer Genomics and Diagnostics, Cancer, Lipids, and Metabolism, and Lung Cancer Treatments and Mutations.
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
Molecular characterization of primary and secondary resistance to RET inhibitors in patients with advanced NSCLC and RET fusions
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial